Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro
It is found that knockdown of PTB expression in the ovarian tumor cell line A2780 substantially impaired tumor cell proliferation, anchorage-independent growth and in vitro invasiveness, and may be a novel therapeutic target in the treatment of ovarian cancer.
ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells
- A. Kol, A. T. V. van Scheltinga, M. Pool, C. Gerdes, E. D. de Vries, S. de Jong
- Biology, ChemistryOncotarget
- 17 April 2017
It is found that imgatuzumab plus cetuximab leads to a strong downregulation of EGFR and superior cell growth inhibition in vitro without affecting antibody-induced ADCC responses, which support further clinical exploration of the antibody combination in EGFR wild-type NSCLC.
Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab
High sEGFR levels can redirect 89Zr-imgatuzumab to the liver, in which case tumor visualization can be improved by increasing tracer antibody dose.
89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment
- M. Pool, A. Kol, S. de Jong, E. D. de Vries, M. L. Lub-de Hooge, A. T. V. Terwisscha van Scheltinga
- 5 September 2017
In vivo HER3 tumor status assessment after lapatinib treatment with zirconium-89 (89Zr)-labeled anti-HER3 antibody mAb3481 positron emission tomography (PET) showed high, HER3-specific tumor uptake, and such an approach might sensitively assess Her3 tumor heterogeneity and treatment response in patients.
Biodistribution and PET Imaging of Labeled Bispecific T Cell–Engaging Antibody Targeting EpCAM
The authors' data support using 89Zr and IRDye 800CW to evaluate tumor and tissue uptake kinetics of bispecific T cell engager antibody constructs in preclinical and clinical settings provides real-time information about AMG 110 distribution and tumor uptake in vivo.
89Zr-Onartuzumab PET imaging of c-MET receptor dynamics
- M. Pool, A. T. V. Terwisscha van Scheltinga, A. Kol, D. Giesen, E. D. de Vries, M. L. Lub-de Hooge
- Medicine, ChemistryEuropean Journal of Nuclear Medicine and…
- 19 March 2017
Results show that 89Zr-onartuzumab PET effectively discriminates relevant changes in c-MET levels and could potentially be used clinically to monitor c- MET status.
Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue
89Zr-CX-072 accumulates specifically in PD-L1–expressing tumors with limited uptake in murine peripheral lymphoid tissues, and this data may enable clinical evaluation of 89Zr’s whole-body distribution as a tool to support CX-72 drug development.
PCR Production of a Digoxigenin‐labeled Probe for the Detection of Human Cytomegalovirus in Tissue Sections
- N. Wood, M. Sheikholeslami, M. Pool, J. Coon
- BiologyDiagnostic molecular pathology : the American…
- 1 September 1994
This method has detected CMV infection in routine clinical specimens from a variety of tissue types, including colon, kidney, liver, and stomach, and may be useful for producing probes for the detection of other viral genomes in tissue sections.
Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition
Analysis of MUC1 using serial blood sampling may be a new, relatively non-invasive tool to monitor early and drug-specific effects of EGFR-targeting therapeutics.
Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine
- M. Pool, H. R. de Boer, M. N. L. Hooge, M. V. van Vugt, E. D. de Vries
- Biology, MedicineTheranostics
- 27 May 2017
It is illustrated how molecular imaging may be employed to characterize whole body target expression as well as monitor drug effectiveness and the emergence of tumor resistance, and how an integrative omics discovery platform could guide the selection of 'effect sensors' - new molecular imaging targets - which indicate treatment effectiveness or resistance.